ArticleBMC gastroenterology2021
Endoscopic mucosal resection: still a reliable therapeutic option for gastrointestinal neuroendocrine tumors.
Article in BMC gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Efficacy of endoscopic mucosal resection versus endoscopic submucosal dissection for rectal neuroendocrine tumors ≤10mm: a systematic review and meta-analysis.Annals of Saudi medicinePooled it
- Successful endoscopic resection of large duodenal bulb carcinoid tumor: a case report.Annals of medicine and surgery (2012) · 2026Article
- Endoscopic Treatment of Gastric Neuroendocrine Tumors: What's Next?Gut and liver · 2025Article
- Long-Term Outcomes in Patients With Non-Ampullary Duodenal Neuroendocrine Tumors.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Management of type I gastric-neuroendocrine tumors: the less the better?Frontiers in endocrinology · 2025Article
- Risk factors for positive resection margins after endoscopic resection for gastrointestinal neuroendocrine tumors.Surgical endoscopy · 2024Article
- Management of Gastric Neuroendocrine Tumors: A Review.Annals of surgical oncology · 2024Review
- Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms.Digestive diseases and sciences · 2024Review
- Long-term outcomes of endoscopic resection for duodenal neuroendocrine tumors.Scientific reports · 2023Article
- Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?Medicina (Kaunas, Lithuania) · 2023Review
- Article
- Endoscopic techniques for gastric neuroendocrine tumors: An update.World journal of gastrointestinal endoscopy · 2023Review
- Endoscopic Resection of Gastrointestinal Neuroendocrine Tumors: Safe and Effective.GE Portuguese journal of gastroenterology · 2023Article
- Role of Endoscopy in Management of Upper Gastrointestinal Cancers.Diseases (Basel, Switzerland) · 2022Review
- Comparison between endoscopic mucosal resection with a cap and endoscopic submucosal dissection for rectal neuroendocrine tumors.BMC surgery · 2022Article
- Nomogram for preoperative estimation of histologic grade in gastrointestinal neuroendocrine tumors.Frontiers in endocrinology · 2022Article
- New Developments in Gastric Neuroendocrine Neoplasms.Current oncology reports · 2022Review
- Endoscopic mucosal resection using a ligation device for duodenal neuroendocrine tumors: a simple method.Therapeutic advances in gastrointestinal endoscopyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroendocrine tumors (NETs), as a rare and heterogeneous category of solid tumors, feature various morphologies and behaviors. In recent years, the incidence of NETs has continued to increase. Endoscopic mucosal resection (EMR) is one of the therapeutic modalities for the treatment of gastric and rectal NETs.
methodsWe evaluated patients with well-differentiated NETs of the stomach, duodenum, or rectum between 2011 and 2018. In this study, all cases with tumors confined to the mucosal or submucosal layers and smaller than 20 mm were resected using the EMR technique. We used EUS, CT scan, or MRI to exclude patients with advanced disease. All patients were actively monitored for recurrence according to the recommended protocols.
resultsA total of 36 patients with NETs entered the study; 17 (47.2%) were female and the remaining 19 (52.8%) were male, with a total age range of 20-74 years (mean: 52.47 ± 13.47 years). Among the tumors, 31 cases (86.1%) were G1 and the remaining 5 (13.9%) were G2. Based on the pathology reports, 22 tumors (61.1%) were smaller than 1 cm, while the remaining 14 (38.9%) were between 1-2 cm. Twenty-two patients (61.1%) had a margin of specimen involved with the tumor. No recurrence was observed during the mean follow-up time of 63.5 ± 19.8 months (range: 39-103 months). All 36 cases survived during the study period.
conclusionConventional EMR procedure provides low chance of R0 (complete resection) achievement in gastrointestinal NETs smaller than 20 mm and limited to the mucosa or sub mucosa. However, it could be an option if patients are closely followed. Postoperative marginal involvement is not a reliable predictor of disease recurrence, which may be explained by the deleterious effect of heat coagulation and cauterization applied during tumor removal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.